Corporacion Parc Tauli
Quick facts
Marketed products
- Bupivacaine 7 mg
- fentanyl 15 microg · Pain Management
Fentanyl is a synthetic opioid agonist that binds to mu-opioid receptors in the central nervous system to produce analgesia and sedation. - Hydrochlorothiazide and furosemide
Phase 3 pipeline
- L-BUPIVACAINE ; MORPHINE · Anesthesia and Pain Management
This combination uses L-bupivacaine (a local anesthetic) and morphine (an opioid analgesic) to provide regional anesthesia and postoperative pain relief through blockade of nerve conduction and opioid receptor activation.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
Frequently asked questions about Corporacion Parc Tauli
What are Corporacion Parc Tauli's marketed drugs?
Top marketed products include Bupivacaine 7 mg, fentanyl 15 microg, Hydrochlorothiazide and furosemide.
What is Corporacion Parc Tauli's pipeline?
Corporacion Parc Tauli has 1 drugs in Phase 3, 0 in Phase 2, 3 in Phase 1. Late-stage candidates include L-BUPIVACAINE ; MORPHINE.
Related
- Bupivacaine 7 mg
- fentanyl 15 microg · Pain Management
- Hydrochlorothiazide and furosemide
- Sector hub: All tracked pharma companies